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Although cancer arises from a combination of mutations in oncogenes and tumour suppressor genes, the extent to which tumour suppressor gene loss is required for maintaining established tumours is poorly understood. p53 is an important tumour suppressor that acts to restrict proliferation in response to DNA damage or deregulation of mitogenic oncogenes, by leading to the induction of various cell cycle checkpoints, apoptosis or cellular senescence 1, 2 . Consequently, p53 mutations increase cell proliferation and survival, and in some settings promote genomic instability and resistance to certain chemotherapies 3 . To determine the consequences of reactivating the p53 pathway in tumours, we used RNA interference (RNAi) to conditionally regulate endogenous p53 expression in a mosaic mouse model of liver carcinoma 4, 5 . We show that even brief reactivation of endogenous p53 in p53-deficient tumours can produce complete tumour regressions. The primary response to p53 was not apoptosis, but instead involved the induction of a cellular senescence program that was associated with differentiation and the upregulation of inflammatory cytokines. This program, although producing only cell cycle arrest in vitro, also triggered an innate immune response that targeted the tumour cells in vivo, thereby contributing to tumour clearance. Our study indicates that p53 loss can be required for the maintenance of aggressive carcinomas, and illustrates how the cellular senescence program can act together with the innate immune system to potently limit tumour growth.
p53 mutations are common in human liver cancer 6 , which is typically highly aggressive and resistant to non-surgical therapies. To determine the requirement for p53 loss in the maintenance of such carcinomas, we used reversible RNAi 7 to control p53 in a chimaeric liver cancer mouse model (Fig. 1a) 4,5 . Purified embryonic liver progenitor cells (hepatoblasts) were transduced with retroviruses expressing oncogenic ras (HrasV12), the tetracycline transactivator protein tTA ('tet-off') and a tet-responsive p53 miR30 design short hairpin RNA (shRNA; Supplementary Fig. 1a ) 7, 8 , and seeded into the livers of athymic nude mice following intrasplenic injection 4, 5 . To facilitate in vivo imaging, the oncogenic ras retrovirus co-expressed green fluorescent protein (GFP) and, in some experiments, hepatoblasts were also co-transduced with a luciferase reporter.
p53 expression was efficiently suppressed in the absence of doxycycline (Dox) and rapidly restored following Dox addition ( Supplementary Fig. 1b, c) . On transplantation into the livers of recipient mice, hepatoblast populations co-expressing Ras and the conditional p53 shRNA rapidly produced invasive hepatocarcinomas in the absence of Dox (Fig. 1b) , whereas cells expressing each vector alone did not (data not shown). These tumours were GFP-positive and, if expressing luciferase, could be visualized externally by bioluminescence imaging (Fig. 1b) .
Animals with advanced tumours were treated with Dox to reestablish p53 expression (Fig. 1b) . Shortly after Dox administration, the p53 microRNA (miRNA) was shut off and p53 expression increased ( Supplementary Fig. 1 ). Although tumours in untreated mice rapidly progressed, those in Dox-treated animals began to involute and became nearly undetectable within 12 days (Fig. 1b) . Similar results were observed in a subcutaneous setting, where tumours could be accurately monitored using calliper measurements (Fig. 1c, left panel) . Importantly, ras-induced liver carcinomas produced using a constitutive p53 shRNA grew similarly irrespective of Dox treatment (Fig. 1c, right) , indicating that tumour regression was not due to Dox toxicity. Such regressions also occurred when p53 was reactivated in tumours co-expressing a constitutively activated Akt or an endogenous oncogenic K-ras allele and the conditional p53 shRNA (W.X., L.Z. and S.W.L., unpublished data).
To determine whether transient p53 reactivation could also cause tumour regression, we treated transformed cells in culture or tumour-bearing mice with Dox for 4 days and then removed the drug. Immunoblotting revealed that p53 could be transiently induced following Dox addition and withdrawal (Fig. 1d) . In cultured cells, even two days of Dox treatment reduced colony formation to levels observed following continuous Dox treatment ( Supplementary Fig. 2a ). Furthermore, both in situ and subcutaneous liver carcinomas showed complete regressions after only four days of Dox treatment ( Fig. 1e; Supplementary Fig. 2b ). Thus, p53 can induce tumour involution through a process that, once activated, seems irreversible. These observations are analogous to results seen in murine tumours conditionally expressing various oncogenes, where silencing of the initiating oncogene often causes tumour regression 9, 10 . The rapid involution of hepatocarcinomas re-expressing p53 is consistent with p53's well-characterized ability to promote apoptosis. We therefore examined apoptosis and proliferation in tumours before and after p53 restoration (Fig. 2a, b) . Surprisingly, we observed few cells that were TUNEL-positive or contained activated caspase 3 following p53 reactivation, suggesting that the primary response to p53 was not apoptosis. Similarly, substantial necrosis was not observed in the regressing tumours. Instead, these tumours showed a marked decrease in proliferation (Ki67) that was associated with signs of cellular differentiation ( Supplementary Fig. 3 ).
p53 can also promote cellular senescence, an apparently irreversible form of cell cycle arrest that is a potent barrier to tumorigenesis [11] [12] [13] [14] and can be triggered by hyperactive Ras or PI3K signalling 12, 15 . Interestingly, hepatocarcinomas expressing either oncogenic ras or Akt showed clear signs of senescence following p53 reactivation in vivo ( Fig. 3a-c ; data not shown for Akt), including the accumulation of senescence-associated-b-galactosidase (SA-b-Gal) activity (Fig. 3a, b) (Fig. 3c ) 13, 15 . SA-b-gal activity was also observed in tumours following brief Dox treatment (Fig. 3b ), indicating that a pulse of p53 activity was sufficient to trigger senescence in vivo.
That p53 activation induces both cellular senescence and tumour involution is surprising given that senescence is a cytostatic program. Indeed, transformed cells accumulated SA-b-gal activity but subsequently remained arrested following p53 reactivation in vitro (Fig. 3d-f) , suggesting that tumour regression involves non-cellautonomous processes. Microscopic examination of tumours harvested at different times following p53 reactivation revealed a progressive inflammatory reaction involving polymorphonuclear leukocytes, initially developing in peri-tumoral regions and ultimately spreading throughout the tumour (Fig. 4a-f) . We also observed an intense perivascular infiltration in regressing tumours, leading eventually to an overt vasculitis characterized by sclerosed vessels, hemorraghia and erythrophagocytosis ( Supplementary Fig.  7 ). Morphological, immunofluorescence and flow cytometric analyses identified the infiltrating leukocytes as neutrophils, macrophages and natural killer cells (Supplementary Figures 4-6 ). These histopathological features support a model of sequential events, initiated by p53 reactivation in the tumour, activation of a dramatic inflammatory response, followed by destruction of tumour cells and neo-vasculature.
Senescent cells often acquire a gene expression signature that includes the upregulation of inflammatory cytokines and other immune modulators 16, 17 . Accordingly, inflammatory cytokines known to attract macrophages (Csf1 and Mcp1), neutrophils (Cxcl1) and natural killer cells (Il15) were upregulated in liver tumours shortly following p53 reactivation (Fig. 4g) . These genes were also induced by p53 in cultured hepatoma cells, demonstrating that they are expressed in tumour cells, not merely the infiltrating leukocytes (Fig. 4g) . Moreover, several adhesion molecules including Icam1 (ref. 18 ) and Vcam1 were induced following p53 reactivation (Fig. 4g, and data not 
To determine whether innate immune cells were required for tumour clearance, mice bearing subcutaneous hepatocarcinomas harbouring the conditional p53 shRNA were treated with gadolinium chloride (a macrophage toxin) 19, 20 or neutralizing antibodies to suppress neutrophil or natural killer cell function 20, 21 , and monitored for tumour regression following Dox treatment. All three treatments significantly delayed tumour regression following p53 reactivation (Fig. 4i) , thus confirming that components of the innate immune system were actively involved in tumour clearance, presumably through a coordinated response. Importantly, each antagonist efficiently and specifically depleted the targeted immune cells from the spleen or peripheral blood ( Supplementary Fig. 8 ), but did not prevent tumour cell senescence (Fig. 4j) . Similarly, almost no tumour regression was observed following p53 reactivation in tumours grown in NOD/SCID mice -which have a highly impaired innate immune system 22 -even though p53 still induced cytostasis and senescence ( Supplementary Fig. 9) . Therefore, the delay in tumour clearance cannot be explained by a failure of the immune system to phagocytose dead or dying cells. Instead, these results indicate that the induction of cellular senescence and the evoked immune attack cooperate to promote tumour clearance. Of note, the athymic nude mice used here lacked functional B and T cells, which typically potentiate, but can also attenuate, inflammatory responses 23 . However, p53 reactivation in murine sarcomas also can induce senescence and tumour clearance in a completely immunocompetent setting 24 . Our study used regulatable RNAi to demonstrate that p53 loss is required for maintenance of aggressive hepatocarcinomas. We suspect that tumours harbouring p53 mutations may be hypersensitive to restoration of p53 signalling because they have oncogenic lesions or damage signals capable of potently activating p53 (refs 3,25) . Still, the consequences of restoring p53 signalling may depend on tumour origin or genotype; thus, whereas p53 reactivation induces senescence in liver carcinomas and sarcomas, lymphoid tumours respond to p53 by undergoing apoptosis 24 . Tumours may also eventually escape their dependence on p53 mutations, but the fact that brief reactivation can cause complete tumour regressions supports the potential of transient p53 reactivation therapies 26, 27 , even for advanced cancers.
Our results also identify a novel mechanism of tumour suppression involving cooperative interactions between a tumour cell senescence program and the innate immune system. They further demonstrate that, despite the cytostatic nature of the senescence program, senescent cells can turn over in vivo. Whether such turnover is a general feature of senescence in vivo is not clear 14, 28 , but when present may reinforce the tumour suppressive action of senescence in pre-malignant settings or in tumours following treatment with senescence-or differentiation-promoting therapies 26, 29 . Conversely, our results identify a setting in which the innate immune system is provoked to coordinately attack tumour cells, presumably through both phagocytosis and direct cytotoxic killing, thereby facilitating their elimination. Although it is established that chronic inflammation triggered by senescent stromal cells or other factors can promote tumorigenesis 19, 30 , our study illustrates how innate immune cellswhen targeted against senescent tumour cells-can have anti-tumour effects as well. Strategies that specifically harness these processes may represent a promising therapeutic approach. 
METHODS
See Supplementary Methods for detailed experimental methods. Generation and analysis of liver tumours. Isolation, culture and retroviral infection of murine hepatoblasts were as described 4, 5 . Doxycycline treatment (BD Biosciences) and bioluminescence imaging (Xenogen) was performed according to the manufacturer's instructions. Histopathological evaluation was performed by an experienced pathologist (C.C.C.). Immunohistochemistry was performed as described 5 . Tumour characterization. Fresh tumour tissue was lysed in Laemmli buffer using a tissue homogenizer and analysed by immunoblotting by standard procedures with the indicated antibodies. Detection of SA-b-gal activity was performed as described at pH 5.5 (ref. 7) . Sections (10 mm) of snap frozen tumour tissue were fixed with 1% formalin for 1 min and stained for 12 h. Tumourbearing livers were fixed with 4% formalin overnight and stained for 4 h. Cultured cells were fixed with 4% formalin for 5 min and stained for 10 h. RNA expression analyses. RNA isolation (Qiagen) and TaqMan reverse transcriptase reaction (Applied Bosystems) were according to the manufacturer's instructions. Quantitative PCR (qPCR) reactions (Bio-Rad) for each sample were done in triplicate. Microarray experiments were performed on Mouse Genome 430A 2.0 arrays (Affymetrix). Data analysis. All the statistical analysis was done by Student's t-test. 
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